Epicardial Cell Sorting for Cardiac Regeneration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for heart failure, particularly post-myocardial infarction, are limited by the heart's inability to regenerate contractile myocardial tissue, leading to irreversible loss and fibrotic scar tissue formation, which impairs heart function and often results in further failure.
Innovation Solution
The development of methods to isolate and separate two distinct populations of in vitro-differentiated human epicardial cells based on transcription factor expression levels (TCF21 and Basonuclin 1) for targeted cell therapy and drug testing, allowing for controlled regeneration of cardiac tissue and reduced fibrosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If in vitro-differentiated human epicardial cells are used for cardiac repair, then regeneration of functional heart tissue is achieved, but the heterogeneous population causes uncontrolled fibrosis and limited therapeutic outcome
Solution Approach 1:
The heterogeneous epicardial cell population is segmented into two distinct subpopulations based on transcription factor expression: TCF21-high cells (which promote fibrosis) and TCF21-low cells (which promote regeneration). This segmentation allows selective use of TCF21-low cells for cardiac repair while excluding TCF21-high cells that would cause harmful fibrosis, thereby resolving the contradiction between achieving regeneration and avoiding fibrosis.
2Productivity
If the epicardium is reactivated after ischemic injury, then EPDC production is initiated, but the cells are less efficient at migrating and differentiating compared to embryonic counterparts
Solution Approach 1:
The patent changes the key parameter of transcription factor expression levels (specifically TCF21) to distinguish between embryonic and adult epicardial cells. By identifying and selecting for cells with embryonic-like transcriptional profiles (high BNC1, low TCF21), the method effectively resets the differentiation efficiency parameter to embryonic levels, overcoming the age-related decline in regenerative capacity.
3Ease of manufacture
If a homogenous population of epicardial cells is assumed for therapy, then simplified treatment protocol is achieved, but the actual heterogeneity leads to uncontrolled biological outcomes
Solution Approach 1:
Instead of treating all epicardial cells uniformly, the patent applies local quality by differentiating between cell subpopulations based on their transcriptional characteristics. The TCF21-low subpopulation is specifically selected for therapeutic use because it provides the desired regenerative effects without the harmful fibrotic effects of TCF21-high cells, thus achieving both protocol simplicity and outcome control.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables the regeneration of functional heart tissue, improves cardiac repair by promoting angiogenesis and cardiomyocyte maturation, and reduces fibrosis, offering a more effective therapeutic approach for heart injuries and diseases.
Implementation Method 1
cell-sorting using a capture agent specific for a cell surface marker for the first population of cells and/or the second population of cells
Data Source
AI summary
The invention relates to in vitro methods for isolating, or producing selected populations of human epicardial cells derived from human pluripotent stem cells; defined mixtures of said cells, and therapeutic uses thereof. Said population comprises epicardial cells with or without the potential to differentiate into cardiac fibroblasts, or a mixture thereof.